SciELO - Scientific Electronic Library Online

 
vol.75 suppl.3Antibodies against Trypanosoma cruzi in patients with dilated cardiomyopathy in Tuxtla Gutierrez, ChiapasLeucocytosis associated with higher incidence of adverse cardiovascular events in myocardial infarcts author indexsubject indexsearch form
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

  • Have no similar articlesSimilars in SciELO

Share


Archivos de cardiología de México

On-line version ISSN 1665-1731Print version ISSN 1405-9940

Abstract

GARCIA GRAULLERA, Roberto de Jesús et al. Levosimendan in patients with acute cardiac failure. Arch. Cardiol. Méx. [online]. 2005, vol.75, suppl.3, pp.55-60. ISSN 1665-1731.

Objective: To assess levosimendan efficacy in acute cardiac failure. Methods: We included 25 patients with acute cardiac failure and partial conventional therapy response defined as persistence of low cardiac output with inotropic support. We started levosimendan at loading dose and continuous infusion for 24 hours, recording hemodynamic data, as well as clinical variables. Results: All patients showed clinical and hemodynamic improvement. Pulmonary wedge capillary pressure (PWCP) decreased from 18 cmH2O (11 -30 cmH2O) to 14 cmH2O (8-15 cmH2O) at 12 hours (p = 0.3) and to 13 cmH2O (8-12 cmH2O) at the end of the infusion period (p = 0.2). Cardiac index increased from 2.1 L/min/m2 (1.8-3.5 L/ min/m2) to 2.86 L/min/m2 (2-4.3 L/min/m2) at 12 hours (p = 0.03) and to 3.08 L/min/m2 at the end of the infusion period (p = 0.02). Tachycardia higherthan 120 bpm was present in six patients. No major hypotensive events were present. Mortality to the present is of eight patients. Conclusion: Levosimendan infusion improved hemodynamics and clinical variables in acute cardiac failure with few side effects in this small series of patients.

Keywords : Levosimendan; Acute heart failure; Hemodynamics parameters.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )

 

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License